Hepatitis D virus infection, innate immune response and antiviral treatments in stem cell-derived hepatocytes

• Published in: Liver international 2023-10, Vol.43 (10), p.2116-2129
• Main Authors: Lange, Frauke, Garn, Jonathan, Anagho, Holda A, Vondran, Florian W R, von Hahn, Thomas, Pietschmann, Thomas, Carpentier, Arnaud
• Format: Article
• Language: English
• Subjects: Antigens; Antiviral agents; Cell differentiation; Drug development; Hepatitis; Hepatitis delta virus; Hepatocytes; Immune response; Immune system; Immunosuppressive agents; Infections; Innate immunity; Inoculation; Interferon; Liver; NF-κB protein; Pathogens; Pluripotency; Polypeptides; Replication; Stem cells; Viral infections; Viruses
• ISSN: 1478-3223; 1478-3231
• DOI: 10.1111/liv.15655

Human pluripotent stem cell (hPSC)-derived hepatocyte-like cells (HLCs) are a valuable model to investigate host-pathogen interactions of hepatitis viruses in a mature and authentic environment. Here, we investigate the susceptibility of HLCs to the hepatitis delta virus (HDV). We differentiated hPSC into HLCs, and inoculated them with infectious HDV produced in Huh7 . HDV infection and cellular response was monitored by RTqPCR and immunostaining. Cells undergoing hepatic differentiation become susceptible to HDV after acquiring expression of the viral receptor Na -taurocholate co-transporting polypeptide (NTCP) during hepatic specification. Inoculation of HLCs with HDV leads to detection of intracellular HDV RNA and accumulation of the HDV antigen in the cells. Upon infection, the HLCs mounted an innate immune response based on induction of the interferons IFNB and L, and upregulation of interferon-stimulated genes. The intensity of this immune response positively correlated with the level of viral replication and was dependant on both the JAK/STAT and NFκB pathway activation. Importantly, this innate immune response did not inhibit HDV replication. However, pre-treatment of the HLCs with IFNα2b reduced viral infection, suggesting that ISGs may limit early stages of infection. Myrcludex efficiently abrogated infection and blocked innate immune activation. Lonafarnib treatment of HDV mono infected HLCs on the other hand led to exacerbated viral replication and innate immune response. The HDV in vitro mono-infection model represents a new tool to study HDV replication, its host-pathogen interactions and evaluate new antiviral drugs in cells displaying mature hepatic functions.